• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1138699 1628 老马 发表于 2011-10-27 08:05:18 | 置顶 |
dg33015426  初中三年级 发表于 2013-1-10 14:07:38 | 显示全部楼层 来自: 浙江杭州
老马你好,我是住大关小区的病友家属,我妈之前在半山肿瘤医院进行的治疗,现复诊可就近到省人民医院检查吗,癌胚抗原指数可做参考吗,我看你爸爸有到中医院或117医院或省人民医院检查,这样和原来的指数能比较吗?
老马  博士一年级 发表于 2013-1-10 14:08:34 | 显示全部楼层 来自: 浙江温州
可以去省医院检查,可以在相近时间,在半山医院和省人民医院都查个血,做个比较。
个人公众号:treeofhope
dg33015426  初中三年级 发表于 2013-1-10 14:10:37 | 显示全部楼层 来自: 浙江杭州
谢谢,明白
dg33015426  初中三年级 发表于 2013-1-10 14:23:43 | 显示全部楼层 来自: 浙江杭州
马先生,你好,我妈2992第33天,20天时验血癌胚抗原16.9降至11.8,但这10天前口腔溃疡至今,是副作用吗,有什么对症办法?谢谢

点评

还可以经常用盐水漱口,效果很好。  发表于 2013-1-10 16:49
是副作用,可以用康复新漱口,另外吃VC泡腾片(力度伸)。  发表于 2013-1-10 14:44
dg33015426  初中三年级 发表于 2013-1-10 14:47:32 | 显示全部楼层 来自: 浙江杭州
谢谢,谢谢
yxp  小学六年级 发表于 2013-1-10 19:16:29 | 显示全部楼层 来自: 上海普陀区
路过踩踩
老马  博士一年级 发表于 2013-1-11 08:35:40 | 显示全部楼层 来自: 浙江温州
Altered Dosing of Vemurafenib Could Delay or Prevent Resistance8 ]9 p1 T; X& a
http://www.cancernetwork.com/mel ... ticle/10165/2122328' l! a. U8 F: W3 d/ c% N/ I/ a/ d; C
n a new study published today in Nature, researchers using a mouse model of melanoma were able to prevent resistance to vemurafenib by altering the dosing schedule from a continuous daily dose to an intermittent dose, suggesting a possible way to prolong the onset of resistance for melanoma patients.
" }' K) y1 r; U* [7 I/ ~Micrograph of pigmented malignant melanoma; source: Nephron, Wikimedia Commons
# ?3 J4 I$ R/ ]1 F7 Z+ ?5 D0 I+ T- n) K+ P, u. j6 a
Vemurafenib (Zelboraf), a small-molecule kinase inhibitor, is the first targeted therapy approved by the US Food and Drug Administration for metastatic melanoma, approved for tumors that express the BRAF V600E gene mutation. Resistance to the drug, however, is problematic, with the vast majority of patients experiencing tumor regrowth several months into treatment.
- O. c5 ?1 y$ J) ]0 t6 P% q; N  |, E
- W8 k9 }0 P" E  F  u    Click here to find out more!, K! b' [1 u; `: H# Z$ _& Z# a8 j

* O# a+ ~& S+ S8 `' vMartin McMahon, PhD, of the Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco (UCSF), and colleagues at the Novartis Institutes for Biomedical Research in Emeryville, California found mouse models that become resistant to vemurafenib with chronic exposure have a continued dependency on the BRAF-MEK-ERK signaling pathway. The vemurafenib-resistant tumor growth that develops is actually dependent on the drug. When the drug administration was stopped, tumor regression was observed within 10 days, followed by tumor regrowth. “These data support the hypothesis that vemurafenib-resistant tumors suffer a fitness deficit in the absence of vemurafenib,” the authors conclude.
9 i( Z3 m" E  b* y3 k8 \) z# V  {& S- w
“Intermittent dosing alternates the selective pressure applied by drug treatment and prevents the evolution of a drug-resistant state,” said Darrin Stuart, PhD, a senior investigator at the Novartis Institutes for Biomedical Research and one of the lead authors of the publication.( ]" w1 A" J! J8 j

. D5 W: t- Y( o1 L! |The resistance mechanism detected was upregulation of BRAF rather than mutations within BRAF or other genes in the signaling pathway.- N! q/ Y0 R! _/ V
. q: U) t# q6 ]
“Even cancer cells are sensitive to the level of oncogenic pathway activation such that too little or too much of a pathway to which a cancer cell is addicted can be deleterious to the cell. This phenomenon is known as the ‘Goldilocks effect’,” explained McMahon.- N0 h; @3 a) j" E( k/ l
8 L& i' |& P6 s7 u: o& {5 x
The results may have major implications for the way targeted therapies against active protein kinases are administered. “The current paradigm for oncoprotein kinase directed therapy is continuous administration—this data hints that continuous therapy may not always be the best approach,” said McMahon.1 q- A  ?3 a% e' y

# m& H$ Q9 X) D: C( V% G6 ~, p. LThe problem is not an easy fix—physicians need to balance maximal tumor regression, typically achieved by continuous treatment, and delaying the onset of resistance, which this study suggests might best achieved with an intermittent drug dose.
  R* ?5 S$ a% w9 f4 w4 @8 Z4 ^
, ]8 x( T( I% W0 [) n+ kMice given vemurafenib continuously on a daily basis developed resistance within 100 days of treatment initiation. In contrast, those mice treated for their melanoma intermittently with a 4 weeks on, 2 weeks off regimen did not develop resistance by day 200 of treatment.
' s: q- m5 G: `( k5 p6 ]  Q
6 ]$ O& ~; t; j5 LIt is not yet possible to identify patients whose tumors are dependent on chronic vemurafenib exposure, said McMahon, but “devising such a test is feasible and ongoing.”) [) F* C( I& \5 Y2 _

( u6 u$ l: t; W% V( _“There is evidence that patients with drug-resistant disease experience tumor regression when dosing is suspended, however, the therapeutic approach to test would be to use intermittent dosing from the beginning and not wait until resistance emerges,” said Stuart.
; r; L& a" `6 C5 ]) }0 I1 ]3 C4 M( E" t: ^( L% K! e4 N+ T
McMahon noted that there is considerable interest at the UCSF Melanoma Clinic to test whether an intermittent dose schedule of vemurafenib and other BRAF V600E inhibitors may increase the duration of responses. “The idea is now out in the clinical community and so fair game for anyone to design an appropriate clinical trial,” said McMahon. Still, more laboratory research is warranted to understand how frequently this type of phenomenon occurs and how too much BRAF V600E activity inhibits the proliferation of melanoma cells addicted to BRAF V600E signaling, said McMahon.# T# i! n9 N5 l1 ~" |

( H/ w7 i2 H+ TIt is possible that changing the dosing schedule of other oral kinase inhibitors could also delay drug resistance in many other tumor types but much more research, both clinical and laboratory, is necessary.+ y  i. `  z0 k3 w& e  o7 w% I
2 b7 x9 y$ V$ }1 Q8 g9 N& o5 v
Multiple clinical trials to test alternative dosing regimens of BRAF and likely other targeted, oral inhibitors are expected over the next few years according to Stuart. Exploring rational drug combinations is another approach that Novartis is taking.
$ y) o4 S  s" l2 E* y( J
, f( D  U: z- L. t4 eThe current study is a public–private sector collaboration between UCSF and the Novartis Institute for Biomedical Research with “a free-flow of information between the two groups as well as open sharing of materials and reagent,” said McMahon. McMahon added that testing the effects of intermittent doses of BRAF inhibitors would likely also be part of such a public–private sector partnership.
个人公众号:treeofhope
戴云草  初中二年级 发表于 2013-1-11 18:19:18 | 显示全部楼层 来自: 福建厦门
老马你好麻烦你了,请问一下吃易时每月除检查CEA以外是否还的检查肝功和血常规呢?。
1 F+ `* }& a8 D/ G' i. q; }
dongjh952  初中二年级 发表于 2013-1-11 20:27:19 | 显示全部楼层 来自: 浙江温州
本帖最后由 dongjh952 于 2013-1-11 20:43 编辑 , ]! H" m& _! ]' b

6 C" H! K  I5 \1 E0 o4 _
# D" A5 V4 x4 |# c9 a+ v谢谢老马回复,经过分析一下,我妈三次赛珍+顺铂后休息20天左右就上易,只吃四个月,是不是EGFR不突变,也就是说易根本没用,前两个月易是每个月拍一次的,稳定,也许是培美有效期内,后面两个月是拍一次。大5mm,2992我想放在后面试,+ ]( f6 o8 _5 X( F3 ^* H! i
请问老马老师用什么方案好,1.试单药健泽怎样,尽管老妈不喜欢化疗,目前身体状态还好,化疗的话对她心理打击大,培美有用想放在后面用?2.继续吃易一个月看看有没有继续增大?3.还是用别的方案?谢谢
dongjh952  初中二年级 发表于 2013-1-11 22:52:27 | 显示全部楼层 来自: 浙江温州
谢谢老马,有没必要再吃一个月易看看,因为老妈对化疗心理打击大

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表